PepGen Stock (NASDAQ:PEPG)

Forecast Ownership Financials Chart

Previous Close

$1.38

52W Range

$1.01 - $7.80

50D Avg

$1.61

200D Avg

$4.04

Market Cap

$104.45M

Avg Vol (3M)

$1.40M

Beta

1.93

Div Yield

PEPG Company Profile

PepGen Inc. is a clinical-stage biopharmaceutical company specializing in the development of oligonucleotide therapeutics designed to treat severe neuromuscular and neurological disorders. Its most advanced candidate, PGN-EDO51 – an EDO peptide – is currently undergoing Phase 1 clinical trials for individuals suffering from Duchenne muscular dystrophy (DMD). The company's pipeline also includes PGN-EDODM1, an EDO peptide-conjugated PMO aimed at myotonic dystrophy type 1, alongside other EDO therapeutic candidates for DMD, specifically PGN-EDO53, PGN-EDO45, and PGN-EDO44. Established in 2018, PepGen Inc. operates from its headquarters in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 06, 2022

Website

PEPG Performance

PEPG Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-97.74M	$-84.77M
Net Income	$-89.66M	$-89.98M	$-78.63M
EBITDA	-	$-89.09M	$-83.58M
Basic EPS	$-2.12	$-2.85	$-3.30
Diluted EPS	$-2.12	$-2.85	$-3.30

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 07, 24 | 4:30 PM

Q4 22Mar 25, 23 | 4:30 PM

Peer Comparison

Ticker	Company
CRBP	Corbus Pharmaceuticals Holdings, Inc.
MOLN	Molecular Partners AG
ALEC	Alector, Inc.
CRDF	Cardiff Oncology, Inc.
NKTX	Nkarta, Inc.
FATE	Fate Therapeutics, Inc.
ELTX	Elicio Therapeutics, Inc.
SAVA	Cassava Sciences, Inc.